DK3563837T5 - Bakteriofagterapi - Google Patents

Bakteriofagterapi Download PDF

Info

Publication number
DK3563837T5
DK3563837T5 DK19172749.4T DK19172749T DK3563837T5 DK 3563837 T5 DK3563837 T5 DK 3563837T5 DK 19172749 T DK19172749 T DK 19172749T DK 3563837 T5 DK3563837 T5 DK 3563837T5
Authority
DK
Denmark
Prior art keywords
bacterio
pharmacy
therapy
pharmacy therapy
bacterio pharmacy
Prior art date
Application number
DK19172749.4T
Other languages
English (en)
Other versions
DK3563837T3 (da
Inventor
Pascal Danglas
Laurent Debarbieux
Original Assignee
Ferring Bv
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv, Pasteur Institut filed Critical Ferring Bv
Application granted granted Critical
Publication of DK3563837T3 publication Critical patent/DK3563837T3/da
Publication of DK3563837T5 publication Critical patent/DK3563837T5/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/10011Details dsDNA Bacteriophages
    • C12N2795/10021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/10011Details dsDNA Bacteriophages
    • C12N2795/10111Myoviridae
    • C12N2795/10132Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/10011Details dsDNA Bacteriophages
    • C12N2795/10111Myoviridae
    • C12N2795/10171Demonstrated in vivo effect
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK19172749.4T 2013-04-30 2014-04-30 Bakteriofagterapi DK3563837T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305568.1A EP2799063A1 (en) 2013-04-30 2013-04-30 Bacteriophage therapy
EP14724663.1A EP2991633B1 (en) 2013-04-30 2014-04-30 Bacteriophage therapy

Publications (2)

Publication Number Publication Date
DK3563837T3 DK3563837T3 (da) 2021-12-06
DK3563837T5 true DK3563837T5 (da) 2022-03-21

Family

ID=48485088

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19172749.4T DK3563837T5 (da) 2013-04-30 2014-04-30 Bakteriofagterapi
DK14724663.1T DK2991633T3 (da) 2013-04-30 2014-04-30 Bakteriofagterapi

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14724663.1T DK2991633T3 (da) 2013-04-30 2014-04-30 Bakteriofagterapi

Country Status (29)

Country Link
US (2) US11040078B2 (da)
EP (3) EP2799063A1 (da)
JP (1) JP6543615B2 (da)
KR (1) KR102215453B1 (da)
CN (1) CN105407872B (da)
AU (1) AU2014261461B2 (da)
BR (1) BR112015027269B1 (da)
CA (1) CA2910539C (da)
DK (2) DK3563837T5 (da)
EA (1) EA034195B1 (da)
ES (2) ES2740124T3 (da)
HK (1) HK1221164A1 (da)
HR (2) HRP20211860T2 (da)
HU (2) HUE044431T2 (da)
IL (1) IL242293B (da)
LT (2) LT2991633T (da)
MX (1) MX366497B (da)
MY (1) MY186607A (da)
NZ (1) NZ713423A (da)
PH (1) PH12015502500B1 (da)
PL (2) PL2991633T3 (da)
PT (2) PT2991633T (da)
RS (2) RS59046B1 (da)
SA (1) SA515370073B1 (da)
SG (1) SG11201508897QA (da)
SI (2) SI2991633T1 (da)
TR (1) TR201910955T4 (da)
WO (1) WO2014177622A1 (da)
ZA (1) ZA201508212B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2799063A1 (en) 2013-04-30 2014-11-05 Ferring B.V. Bacteriophage therapy
EP3595689A4 (en) * 2017-03-14 2020-12-09 Brigham Young University METHODS AND COMPOSITIONS FOR TREATING OBESITY, INFLAMMATION OR METABOLIC DISORDERS WITH BACTERIOPHAGES
CN111801107A (zh) * 2017-09-08 2020-10-20 学校法人庆应义塾 用于调节炎性肠病的细菌噬菌体
US11986502B2 (en) 2018-05-23 2024-05-21 Optium, LLC Bacteriophage compositions and kits and related methods
EP3796781A4 (en) * 2018-05-23 2022-04-20 Brigham Young University BACTERIOPHAGE COMPOSITIONS, AND KITS AND RELATED METHODS
IL294166A (en) * 2019-12-23 2022-08-01 Entasis Therapeutics Inc Management of microbial dysbiosis with tamocillin
US20220323517A1 (en) * 2021-04-10 2022-10-13 Intron Biotechnology, Inc. Compositions and methods for inhibiting the proliferation of enterotoxigenic bacteroides fragilis
US20220331381A1 (en) * 2021-04-10 2022-10-20 Intron Biotechnology, Inc. Compositions and methods for inhibiting the proliferation of enterotoxigenic bacteroides fragilis
US20220323518A1 (en) * 2021-04-10 2022-10-13 Intron Biotechnology, Inc. Compositions and methods for inhibiting the proliferation of enterotoxigenic bacteroides fragilis
JP2024515351A (ja) 2021-04-22 2024-04-09 フェリング・ベー・フェー 付着性侵入性大腸菌(Escherichia coli)に対するバクテリオファージ療法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020013270A1 (en) * 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
GB0019721D0 (en) * 2000-08-10 2000-09-27 Regma Biotechnologies Ltd Novel method
EP2377883A1 (en) * 2010-04-15 2011-10-19 Universite d'Auvergne Clermont I Antagonists for the prevention or treatment of inflammatory bowel disease, and more particularly of Crohn's disease
ES2956367T3 (es) * 2010-09-17 2023-12-20 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Fago antibacteriano, péptidos de fago y sus métodos de uso
WO2013045863A1 (fr) * 2011-09-29 2013-04-04 Institut Pasteur Detection de souches e.coli de serotype o104
EP2799063A1 (en) 2013-04-30 2014-11-05 Ferring B.V. Bacteriophage therapy

Also Published As

Publication number Publication date
HRP20211860T2 (hr) 2022-03-18
CN105407872B (zh) 2020-06-12
WO2014177622A1 (en) 2014-11-06
SG11201508897QA (en) 2015-11-27
EP2991633B1 (en) 2019-06-19
PL2991633T3 (pl) 2019-10-31
EP2799063A1 (en) 2014-11-05
ZA201508212B (en) 2022-03-30
CN105407872A (zh) 2016-03-16
CA2910539C (en) 2022-05-17
MY186607A (en) 2021-07-30
JP2016519126A (ja) 2016-06-30
HK1221164A1 (zh) 2017-05-26
LT2991633T (lt) 2019-07-25
BR112015027269B1 (pt) 2023-04-25
HUE056968T2 (hu) 2022-04-28
CA2910539A1 (en) 2014-11-06
HUE044431T2 (hu) 2019-10-28
EA201591979A1 (ru) 2016-04-29
US20210386805A1 (en) 2021-12-16
NZ713423A (en) 2020-07-31
US11918613B2 (en) 2024-03-05
EA034195B1 (ru) 2020-01-16
RS62644B9 (sr) 2022-04-29
KR102215453B1 (ko) 2021-02-15
SI3563837T1 (sl) 2022-04-29
BR112015027269A2 (pt) 2017-09-26
DK3563837T3 (da) 2021-12-06
KR20160005728A (ko) 2016-01-15
HRP20191363T1 (hr) 2019-11-01
AU2014261461A1 (en) 2015-11-12
LT3563837T (lt) 2021-12-27
TR201910955T4 (tr) 2019-08-21
PL3563837T3 (pl) 2022-02-07
PH12015502500A1 (en) 2016-02-22
ES2740124T3 (es) 2020-02-05
EP3563837A1 (en) 2019-11-06
PT2991633T (pt) 2019-08-07
EP3563837B1 (en) 2021-10-20
JP6543615B2 (ja) 2019-07-10
MX366497B (es) 2019-07-11
EP2991633A1 (en) 2016-03-09
RS62644B1 (sr) 2021-12-31
US11040078B2 (en) 2021-06-22
DK2991633T3 (da) 2019-07-29
SA515370073B1 (ar) 2018-02-12
HRP20211860T1 (hr) 2022-03-04
AU2014261461B2 (en) 2019-04-18
IL242293B (en) 2019-09-26
ES2902599T3 (es) 2022-03-29
EP3563837B9 (en) 2022-02-16
MX2015015092A (es) 2016-06-07
US20160143965A1 (en) 2016-05-26
SI2991633T1 (sl) 2019-09-30
PH12015502500B1 (en) 2016-02-22
PT3563837T (pt) 2021-12-03
RS59046B1 (sr) 2019-08-30

Similar Documents

Publication Publication Date Title
BR302013004871S1 (pt) Configuração aplicada em garrafa
BR302013004873S1 (pt) Configuração aplicada em garrafa
DK3563837T3 (da) Bakteriofagterapi
BR302013004490S1 (pt) Configuração aplicada em garrafa
DK3590499T3 (da) Inhalerbare lægemidler
BR302013004136S1 (pt) Configuração aplicada em garrafa
BR302013003480S1 (pt) Configuração aplicada em frasco
DK2976101T3 (da) Behandlingsfremgangsmåde
DK2972363T3 (da) Immunpotenserende nanobærerlægemiddel
FI10329U1 (fi) Kaasujen käsittelylaitteisto
FI20136034A (fi) Sauna
DK3041506T3 (da) Behandlingsfremgangsmåde
UA28711S (uk) Масажер
UA28338S (uk) Медичний пристрій-шприц
UA28339S (uk) Медичний пристрій-шприц
BR302013004832S1 (pt) Configuração aplicada em pílula
BR302013005348S1 (pt) Configuração aplicada em ambulância
UA28963S (uk) Пляшечка на ліки
UA28964S (uk) Пляшечка на ліки
BR302013002006S1 (pt) Configuração introduzida em frasco
BR302013005343S1 (pt) Configuração aplicada em garrafa
BR302013005083S1 (pt) Configuração aplicada em frasco
BR302013004823S1 (pt) Configuração aplicada em garrafa
BR302013004722S1 (pt) Configuração aplicada em frasco
BR302013004691S1 (pt) Configuração aplicada em garrafa